| Literature DB >> 19821998 |
Megan Moerdyk-Schauwecker1, Sun-Il Hwang, Valery Z Grdzelishvili.
Abstract
BACKGROUND: Vesicular stomatitis virus (VSV) is the prototypic rhabdovirus and the best studied member of the order Mononegavirales. There is now compelling evidence that enveloped virions released from infected cells carry numerous host (cellular) proteins some of which may play an important role in viral replication. Although several cellular proteins have been previously shown to be incorporated into VSV virions, no systematic study has been done to reveal the host protein composition for virions of VSV or any other member of Mononegavirales.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19821998 PMCID: PMC2770056 DOI: 10.1186/1743-422X-6-166
Source DB: PubMed Journal: Virol J ISSN: 1743-422X Impact factor: 4.099
Figure 1Overview of the experimental procedure used in this study.
Figure 2Characterization of purified VSV virion preparations. (A) Electron micrographs of the purified virion preparations from BHK21 (two different fields are shown), 4T1 and A549. Virions were absorbed to carbon-formvar coated grids and negatively stained with 2% uranyl acetate. (B) Infectivity (PFU/ml) of purified virions shown in (A) was calculated by standard plaque assay on BHK21 cells. Total protein concentration of these preparations was determined using a Bradford assay, and infectivity per total protein (PFU/μg) was calculated based on these two values. (C) Total RNA was extracted from uninfected (mock) or infected BHK21 cells or from purified virion samples containing 25 μg of protein, and analyzed by Northern blotting. RNA was separated on a 1.5% agarose-formaldehyde gel, transferred to a nylon membrane and detected using a probe complimentary to the 3' end of VSV genome. (D) 50 μg of total protein from each purified virion preparation was separated on a 10% SDS-PAGE gel, and stained with Coomassie Brilliant Blue R250. Numbered boxes indicate the gel segments cut out and analyzed by mass spectrometry.
Cellular proteins identified in purified virion preparations following 1-D SDS-PAGE and LC-MS/MS
| Tubulin alpha | H | IPI00180675 | 50.1 | 3(11/9) | Influenza [ | ||
| M | IPI00110753 | 50.1 | 3(11/10) | 9(2/2) | 15(2/2) | ||
| Annexin A2 | H | IPI00455315 | 38.6 | 2(8/4) | 8(4/3) | 14(3/2) | Influenza [ |
| M | IPI00468203 | 38.5 | 2(12/7) | 8(5/4) | 14(2/2) | ||
| Elongation factor 1-alpha | H | IPI00014424 | 50.5 | 3 (9/3) | 9(9/4) | HIV-1 [ | |
| M | IPI00307837 | 50.3 | 3(9/3) | 9(13/6) | 15(3/2) | ||
| Ubiquitin | H | IPI00719280 | 25.8 | 2(6/3),3(4/3), 4(3/2),5(3/2) | 8(8/3),9(7/3), 11(2/2) | 14(3/2), 17(2/2) | Influenza [ |
| M | IPI00923013 | 26.6 | 2(5/2),3(4/3), 4(3/2),5(3/2) | 8(7/3),9(6/2), 10(2/2), 11(2/2) | 14(3/2), 15(3/2), 17(2/2) | ||
| Integrin beta-1 | H | IPI00217561 | 91.7c | 6(2/2) | 12(3/2) | 18(6/2) | Influenza [ |
| M | IPI00132474 | 88.2c | 6(3/3) | 12(4/3) | |||
| Tubulin, beta | H | IPI00011654 | 49.7 | 3(11/7) | 9(3/3) | Influenza [ | |
| M | IPI00109061 | 49.9 | 3(9/6) | 9(3/3) | |||
| Actin, cytoplasmic | H | IPI00021439 | 41.7 | 4(3/2) | 8(3/3) | Influenza [ | |
| M | IPI00110850 | 41.7 | 4(3/2) | 8(3/3) | |||
| Elongation factor 2 | M | IPI00466069 | 95.2 | 5(2/2) | 11(3/2) | HIV-1 [ | |
| Transferrin receptor protein 1 | H | IPI00022462 | 84.9c | 17(3/2) | HSV-1 [ | ||
| M | IPI00124700 | 85.7c | 11(2/2) | ||||
| Low-density lipoprotein receptor-related protein 1, 85 kDa and 515 kDa subunits | H | IPI00020557 | 504.5 | 5(7/5), 6 (33/27) | |||
| M | IPI00119063 | 504.7 | 5(7/5), 6(38/29) | ||||
| Hsp90 | H | IPI00784295 | 84.8 | 5(8/7) | HIV-1[ | ||
| M | IPI00330804 | 84.6 | 5(8/8) | ||||
| Neural cell adhesion molecule 1 | H | IPI00435020 | 93.3c | 2(2/2), 6(7/6) | |||
| M | IPI00122971 | 119.3c | 6(6/5) | ||||
| Heat shock cognate 71 kDa protein | H | IPI00003865 | 70.9 | 5 (8/6) | MMLV [ | ||
| M | IPI00323357 | 70.9 | 5(3/3) | ||||
| Chondroitin sulfate proteoglycan 4 | H | IPI00019157 | 250.5 | 6(3/3) | |||
| M | IPI00128915 | 252.4 | 6(5/5) | ||||
| Prostaglandin F2 receptor negative regulator | H | IPI00022048 | 98.5c | 6(4/4) | MMLV [ | ||
| M | IPI00125497 | 106.0c | 6(4/4) | ||||
| Enolase | H | IPI00216171 | 47.1 | 3(2/2) | Influenza [ | ||
| M | IPI00462072 | 47.0 | 3(4/4) | ||||
| Annexin A5 | H | IPI00329801 | 35.8 | 2(5/3) | Influenza [ | ||
| M | IPI00317309 | 35.7 | 2(4/2) | ||||
| Synaptic vesicle membrane protein VAT-1 homolog | H | IPI00156689 | 41.9 | 3(4/3) | |||
| M | IPI00126072 | 43.1 | 3(2/2) | ||||
| Annexin A4 | M | IPI00353727 | 35.8 | 2(3/2) | Influenza [ | ||
| ATP synthase alpha chain, mitochondrial | H | IPI00440493 | 59.7 | 3(2/2) | |||
| M | IPI00130280 | 59.7 | 3(2/2) | ||||
| ATP synthase beta chain, mitochondrial | M | IPI00468481 | 56.3 | 3(2/2) | HIV-1 [ | ||
| Casein kinase I | H | IPI00167096 | 39.1 | 2(2/2) | |||
| M | IPI00330729 | 38.9 | 2(2/2) | ||||
| CD44 antigen | H | IPI00297160 | 39.4c | 5(3/2) | HIV-1 [ | ||
| M | IPI00223769 | 40.2c | 5(2/2) | ||||
| Fascin | M | IPI00353563 | 54.3 | 3(2/2) | VV [ | ||
| Fibronectin | M | IPI00113539 | 272.5 | 12(2/2) | HIV-1 [ | ||
| Guanine nucleotide-binding protein G(o), alpha subunit 2 | M | IPI00115546 | 39.9 | 2(3/2) | |||
| Histone H3.2 | M | IPI00230730 | 15.2 | 1(2/2) | |||
| Histone H4 | H | IPI00453473 | 11.2 | 1(2/2) | MMLV [ | ||
| M | IPI00329998 | 11.4 | 1(2/2) | ||||
| Methyl-CpG-binding domain protein 4 | M | IPI00321709 | 62.6 | 3(2/2) | |||
| Monocyte differentiation antigen CD14 | M | IPI00308990 | 39.2 | 3(3/2) | HIV-1 [ | ||
| Pyruvate kinase | M | IPI00407130 | 58.0 | 3(2/2) | Influenza [ | ||
| Integrin alpha-3 | M | IPI00126090 | 116.7c | 12(7/5) | HIV-1 [ | ||
| Annexin A3 | M | IPI00132722 | 36.2 | 8(4/4) | |||
| Envelope protein | M | IPI00406960 | 73.6 | 7(6/4) | |||
| Basigin | M | IPI00113869 | 29.7 | 9(3/3) | HIV-1 [ | ||
| EH-domain-containing protein 1 | H | IPI00017184 | 60.6 | 9(3/3) | |||
| M | IPI00126083 | 60.6 | 9(3/3) | ||||
| Gag protein | M | IPI00224370 | 60.3 | 7(4/3) | |||
| Lymphocyte antigen 74 | M | IPI00115558 | 35.0 | 8(3/3) | |||
| Tumor susceptibility gene 101 protein | H | IPI00018434 | 43.9 | 9(3/3) | HIV-1 [ | ||
| M | IPI00117944 | 44.1 | 9(3/3) | ||||
| Acid sphingomyelinase-like phosphodiesterase 3b | M | IPI00117534 | 51.6 | 9(2/2) | |||
| Dystrophin | M | IPI00474450 | 425.8 | 8(2/2) | |||
| Guanine nucleotide-binding protein G(I)/G(S)/G(T) beta subunit | H | IPI00003348 | 37.2 | 8(3/2) | |||
| M | IPI00116938 | 37.2 | 8(3/2) | ||||
| H-2 class I histocompatibility antigen, D-D alpha chain | M | IPI00110805 | 41.1 | 9(2/2) | |||
| H-2 class I histocompatibility antigen, L-D alpha chain | M | IPI00109996 | 40.7 | 9(2/2) | |||
| L-lactate dehydrogenase A chain | M | IPI00319994 | 36.3 | 8(2/2) | HCMV [ | ||
| Monocarboxylate transporter 1 | M | IPI00137194 | 53.3 | 8(2/2) | |||
| Myosin-9 | H | IPI00019502 | 226.4 | 12(2/2) | VV [ | ||
| T-complex protein 1 subunit beta | M | IPI00320217 | 57.3 | 9(2/2) | HIV-1 [ | ||
| Transmembrane protease, serine 11E | M | IPI00222870 | 50.0 | 9(2/2) | |||
| Ubiquitin protein ligase E3 component n-recognin 4 | M | IPI00378681 | 572.3 | 8(2/2) | |||
| 4F2 cell-surface antigen heavy chain | H | IPI00027493 | 57.9c | 17(9/7) | HIV-1 [ | ||
| Albumin | H | IPI00022434 | 71.7 | 14(3/3) | HIV-1 [ | ||
| Annexin A1 | H | IPI00218918 | 38.6 | 14(3/3) | Influenza [ | ||
| CD109 antigen | H | IPI00152540 | 161.7 | 18(3/3) | |||
| Transmembrane protein 2 | H | IPI00170706 | 154.4 | 18(3/3) | |||
| Aminopeptidase N | H | IPI00221224 | 109.4 | 18(2/2) | HIV-1 [ | ||
| Integrin alpha-V | M | IPI00319509 | 109.5 | 18(2/2) | HIV-1 [ | ||
| H | IPI00027505 | 116.0 | 18(2/2) | ||||
| Lutheran blood group glycoprotein | H | IPI00002406 | 67.4c | 17(2/2) | |||
| Neutral amino acid transporter B(0) | H | IPI00019472 | 56.6c | 17(2/2) | |||
| Programmed cell death 6 interacting protein | H | IPI00246058 | 96.8 | 17(2/2) | MMLV [ | ||
| Ras-related protein Rab-11B | M | IPI00135869 | 24.3 | 13(2/2) | |||
| Ras-related protein Rap-1A | M | IPI00138406 | 21.0 | 13(2/2) | HIV-1 [ | ||
| Solute carrier family 2, facilitated glucose transporter member 1 | H | IPI00220194 | 54.1c | 17(2/2) | |||
| M | IPI00308691 | 53.9c | 17(2/2) | ||||
| T-complex protein 10a | M | IPI00122340 | 47.1 | 18 (3/2) | |||
a From search of human (H) or mouse (M) database
b International protein index accession numbers
c Glycosylated protein
d Gel bands were numbered as depicted in Figure 2D
e ASFV, African swine fever virus; AlHV-1, Alcelaphine herpesvirus-1; AcNPV, Autographa californica nuclear polyhedrosis virus; EBV, Epstein-Barr virus; HCMV, human cytomegalovirus; HIV-1, human immunodeficiency virus-1; KSHV, Kaposi's sarcoma-associated herpesvirus; MV, measles virus, MMLV, Moloney murine leukemia virus; MCMV, murine cytomegalovirus; NDV, Newcastle disease virus; RV, rabies virus; SeV, Sendai virus; SARS-CoV, severe acute respiratory syndrome coronavirus; SIV, simian immunodeficiency virus; VV, vaccinia virus
Figure 3Verification of protein incorporation within the virion preparations. Purified virion preparations (shown in Figure 2A) were left untreated (-ProK) or were treated with Proteinase K (+ProK) for 1.5 h at 37°C to remove all surface exposed proteins. Following ProK treatment, one 4T1-derived virion sample was also centrifuged through a 20% sucrose gradient to remove ProK and free floating peptides (+ProK +Purify). (A) 5 μg of total protein from untreated purified virions or the viral protein equivalent from the ProK treated samples were separated on a 10% SDS-PAGE gel and stained with Coomassie Brilliant Blue R250. Asterisk indicates position of the ProK protein above the M protein. G degr., indicates VSV G protein fragment(s) generated as a result of ProK treatment. (B-D) Immunoblots were performed using 10 μg cellular lysate from mock infected or VSV-wt (+VSV) infected cells harvested at 18 h p.i. or 10 μg of heat shocked (+heat) cellular lysates harvested after a 4 h incubation at 43°C, and 50 μg of total protein from ProK treated or untreated purified virion preparations. Proteins were separated on gradient 8-16% (B and C) or 15% SDS-PAGE (D) gels, transferred to PVDF membranes and rapidly stained with the reversible dye Ponceau S prior to the use of antibodies to confirm levels of viral proteins (cellular proteins were not detectable). Primary antibodies were against integrin β1, heat shock protein 90 kDa (Hsp90), translation elongation factor 1 alpha (EF1α), annexin 2, heat shock cognate 70 kDa (Hsc70), stress-inducible 70 kDa heat shock protein (Hsp72), and cyclophilin A, as indicated.